Speculative share with great results ATL1102 drug, used in the treatment of DMD.
Antisense is looking to advance ATL1102 into a potentially pivotal Phase IIb clinical trial with the goal of providing treatment options to all, not just some, of the boys with DMD.
Due to Antisense's recent trial results, the addressable markets it can target and the positive momentum in the space it operates, Antisense is a key stock to consider, particularly as there are no other listed companies working in this space.
mangement buying shares on the market. Good sign